| 2.75 0 (0%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.1  |
1-year : | 6.42 |
| Resists | First : | 4.36 |
Second : | 5.5 |
| Pivot price | 3.08 |
|||
| Supports | First : | 2.53 | Second : | 2.11 |
| MAs | MA(5) : | 2.8 |
MA(20) : | 3.25 |
| MA(100) : | 7.55 |
MA(250) : | 23.66 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 7.7 |
D(3) : | 6.6 |
| RSI | RSI(14): 31.7 | |||
| 52-week | High : | 127.19 | Low : | 2.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ISPC ] has closed above bottom band by 14.9%. Bollinger Bands are 71.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.93 - 2.94 | 2.94 - 2.96 |
| Low: | 2.67 - 2.69 | 2.69 - 2.71 |
| Close: | 2.72 - 2.75 | 2.75 - 2.78 |
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Tue, 02 Jun 2026
iSpecimen Receives Nasdaq Noncompliance Notice, Listing at Risk - The Globe and Mail
Mon, 01 Jun 2026
iSpecimen Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Mon, 01 Jun 2026
iSpecimen (NASDAQ: ISPC) falls below Nasdaq equity listing requirement - Stock Titan
Fri, 29 May 2026
iSpecimen (ISPC) investors approve director, auditor and 2025 stock incentive plan - Stock Titan
Fri, 01 May 2026
ISPC Stock Explodes Higher As Traders Target Low-Float Runner - StocksToTrade
Fri, 24 Apr 2026
iSpecimen announces 1-for-40 reverse stock split effective Monday - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.44e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 138 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.68e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 627 % |
| Return on Equity (ttm) | -91.8 % |
| Qtrly Rev. Growth | 1.03e+006 % |
| Gross Profit (p.s.) | -48.69 |
| Sales Per Share | -511.2 |
| EBITDA (p.s.) | -174011 |
| Qtrly Earnings Growth | -329.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 4.37 |
| Dividend | 0 |
| Forward Dividend | 112840 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|